DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

Stelo CGM Launch: In August 2024, DexCom announced the commercial launch of Stelo CGM, the first over-the-counter glucose sensor in the U.S. for non-insulin using Type 2 diabetes and prediabetes ...

Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...

DexCom’s strong revenue growth projection for 2025, driven by continued market expansion, broader access wins and advancements in its CGM technology, looks promising. Key plans include the ...